0QLN.LSE Tecan Group AG
- Market cap
- GBP 1.39B
- P/E
- 24.1x
- P/B
- -
- ROE
- 4.4%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 0QLN.LSE undervalued?
Graham numberThe Graham number of Tecan Group AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tecan Group AG fundamental analysis
No fundamental analysis for Tecan Group AG yet.
Tecan Group AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PA…
Full company profileTecan Group AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tecan Group AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 506M | 549M | 594M | 637M | 731M | 947M | 1.14B | 1.07B | 934M | 882M | 1.71B |
| Gross Profit | 225M | 248M | 264M | 283M | 340M | 388M | 405M | 390M | 282M | 280M | 580M |
| Operating Income | 70.2M | 81.1M | 86.7M | 88.9M | 123M | 141M | 146M | 136M | 74.7M | 25.2M | 73.8M |
| EBITDA | 86.7M | 103M | 106M | 118M | 155M | 201M | 211M | 206M | 148M | 86.2M | 187M |
| Net Income | 54.5M | 65.9M | 70.7M | 73.2M | 104M | 122M | 121M | 132M | 67.7M | -111M | 49.1M |
| EPS | 4.66 | 5.59 | 5.96 | 6.13 | 8.62 | 9.88 | 9.47 | 10 | 5.29 | -8.74 | 3.96 |
| Balance Sheet | |||||||||||
| Total Assets | 736M | 804M | 858M | 940M | 1.13B | 2.04B | 2.16B | 2.07B | 2.17B | 1.80B | 1.65B |
| Total Liabilities | 249M | 254M | 245M | 281M | 380M | 800M | 776M | 725M | 721M | 639M | 530M |
| Shareholders' Equity | 487M | 550M | 612M | 659M | 734M | 1.22B | 1.36B | 1.35B | 1.44B | 1.15B | 1.12B |
| Cash & Short-term Investments | 250M | 309M | 297M | 317M | 471M | 242M | 293M | 366M | 406M | 313M | 225M |
| Total Debt | 12.0M | 17.2M | 7.23M | 47.9M | 38.7M | 314M | 308M | 317M | 322M | 219M | 214M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 119M | 99.2M | 92.3M | 98.8M | 208M | 170M | 128M | 161M | 151M | 140M | 68.5M |
| Capital Expenditure | 14.3M | 19.6M | 26.2M | 9.41M | 23.8M | 27.1M | 23.1M | 19.4M | 15.3M | 15.1M | 23.4M |
| Free Cash Flow | 105M | 79.5M | 66.2M | 89.4M | 185M | 143M | 105M | 141M | 136M | 124M | 45.1M |
| Ratios | |||||||||||
| ROE | 11.2% | 12.0% | 11.5% | 11.1% | 14.1% | 9.9% | 8.9% | 9.8% | 4.7% | -9.6% | 4.4% |
| ROA | 7.4% | 8.2% | 8.2% | 7.8% | 9.2% | 6.0% | 5.6% | 6.4% | 3.1% | -6.2% | 3.0% |
| Net Profit Margin | 10.8% | 12.0% | 11.9% | 11.5% | 14.2% | 12.9% | 10.6% | 12.3% | 7.2% | -12.5% | 2.9% |
| Debt to Equity | 0.02x | 0.03x | 0.01x | 0.07x | 0.05x | 0.26x | 0.23x | 0.23x | 0.22x | 0.19x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tecan Group AG dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | 38.0M | 3.00 | - |
| 2024 | CHF 38.3M | 3.00 | 56.6% |
| 2023 | CHF 37.0M | 2.89 | 28.0% |
| 2022 | GBP 35.6M | 2.78 | 29.4% |
| 2021 | GBP 27.6M | 2.24 | 22.7% |
| 2020 | GBP 26.2M | 2.18 | 25.3% |
| 2019 | GBP 24.8M | 2.08 | 33.9% |
| 2018 | GBP 23.5M | 1.98 | 33.2% |
| 2017 | GBP 20.3M | 1.72 | 30.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tecan Group AG
- Insiders 0.43%
- Institutions 66.56%
- Public & others 33.02%
- Shares outstanding 11.8M
- Free float 12.3M
Tecan Group AG company profile
- Company name
- Tecan Group AG
- Ticker
- 0QLN.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 3,000
- Fiscal year end
- December
- Address
- Seestrasse 103, Männedorf, Switzerland, 8708
- Phone
- 41 44 922 81 11
- Website
- tecan.com
About Tecan Group AG
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.
Tecan Group AG management
10- Ms. Monica ManotasCEO, Interim Head of the Partnering Business division & Member of Management Board · born 1973
- Ms. Camila JapurChief Financial Officer · born 1982
- Mr. Andreas WilhelmEVP of Legal, Qua. & Regu. Affairs, Gen. Cou., Sec. of the Board of Dir. & Mem. of Mgmt Board · born 1969
- Dr. Ulrich KanterExecutive VP, Global Head of Operations & IT and Member of Management Board · born 1963
- Mr. Erik Norström B.Sc., M.Sc.Head of Corporate Development, Executive VP & Member of Management Board · born 1973
- Ms. Ingrid PurgstallerChief People Officer & Member of the Management Board · born 1980
- Ms. Mukta AcharyaEVP, Head of the Life Sciences Business Division & Member of the Management Board · born 1984
- Mr. Carsten BoeghEVP, CTO, Head of Research and Development & Member of Management Board · born 1968
- Mr. Martin BrandleSenior Vice President of Corporate Communications & IR
- Mr. Wolfgang DeuringerPresident of Sales International